A Virtuous Cycle: What The Immuno-Oncology Revolution Means For Other Disease Areas
Executive Summary
Execs from Merck, Pfizer, Bristol, Abbvie and smaller biopharmas weigh in on how developments in cancer research may benefit other disease areas, especially autoimmune and neurological conditions.
You may also be interested in...
Finance Watch: A Plethora Of Big Rounds, Led By Gossamer's $230m Series B
Private Company Edition: Gossamer, Ascentage and Alector continued the trend of large venture capital rounds, recently raising $230m, $150m and $133m, respectively. Led by former Receptos executives, Gossamer has multiple clinical trials planned, but continues to keep details of its drug candidates under wraps.
Scrip's Rough Guide To IL-2: Mother Of All Cytokines
Nektar Therapeutics, Alkermes and Roche are among the companies with new solutions for more safely targeting an old cytokine well validated in cancer immunotherapy. Top execs explain how and why.
BMS Q&A: Hunting For Biomarkers To Improve Treatment Of Autoimmune Diseases
Bristol-Myers R&D leaders Brian Gavin and Sean Connolly offered insight into the company's immunology focus for autoimmune diseases, which increasingly is driven by a search for biomarkers that point to the best use of the big pharma's drugs.